Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Pacira Pharmaceuticals (PCRX) PT Raised to $67 at BMO Capital
February 28, 2022 8:49 AM ESTBMO Capital analyst Gary Nachman raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $67.00 (from $62.00) while maintaining a Market Perform rating following results.
The analyst commented, "4Q beat although rev. was preannounced, but margin improvement coming through and should accelerate following... More
Pacira Pharma (PCRX) Tops Q4 EPS by 9c
February 24, 2022 8:04 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.99, $0.09 better than the analyst estimate of $0.90. Revenue for the quarter came in at $159.2 million versus the consensus estimate of $155.74 million.
GUIDANCE:
Today the company is providing full-year 2022 operating expense guidance as... More
